The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe are thoroughly working toward the development of new drug therapy options to treat this disease.

today announced that the first Friedreich ataxia (FA) patient has been dosed via intravenous (IV) infusion in its RESTORE-FA (Reactivating Expression Suppressed Through Overcoming Repeat Expansion ...

Their results are described in a Nature Genetics paper published this week titled “Base editing of trinucleotide repeats that cause Huntington’s disease and Friedreich’s ataxia reduces ...

June 04, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that ...

The dosing of the first Friedreich ataxia patient in the RESTORE-FA trial marks a significant milestone in the clinical development of DT-216P2, showcasing progress in addressing this degenerative ...

Cardiac prophylactic treatment began before age 14 for 27.7% of the cohort. Compared with patients not treated prophylactically, treatment was associated with a 54% reduction in death.

"Dr. Gottesfeld's work holds tremendous promise of real therapeutic benefit for Friedreich's ataxia patients," said Ron Bartek, president of Friedreich's Ataxia Research Alliance (FARA).

Mitchell, who graduated last week with a Bachelor of Entrepreneurship from Otago University, has Friedreich’s ataxia (FA)- a progressive, incurable neurodegenerative muscular disorder.

Most Hamilton and Waikato MRI radiology services will merge under a joint venture proposal from the region’s radiology companies being considered by competition watchdog the Commerce Commission.